DiaSorin launches LIAISON® Measles IgG and LIAISON® Mumps IgG assays (available outside the US and Canada only)

20/06/2011

DiaSorin announces the successful development of two new assays for the semi-quantitative determination of antibodies to measles and mumps viruses on the LIAISON® instrument: LIAISON® Measles IgG and LIAISON® Mumps IgG.
The LIAISON® Measles IgG and LIAISON® Mumps IgG assays are intended for in vitro diagnostic use to aid in the determination of serological status to measles and mumps virus. The LIAISON® Measles IgG and LIAISON® Mumps IgG assays use chemiluminescence immunoassay technology on the LIAISON® Analyzer for the semi-quantitative determination of IgG antibodies to measles and mumps viruses in human serum or plasma.
The introduction of the DiaSorin LIAISON® Measles IgG and LIAISON® Mumps IgG assays provide the first and only fully automated chemiluminescence immunoassays for measles IgG and mumps IgG in the diagnostic market, completing the LIAISON® MMRV IgG panel of assays. DiaSorin’s LIAISON® Measles, Mumps, Rubella and Varicella Zoster IgG Assays are fully automated semi-quantitative or quantitative serology assays, with each having a time-to-first result of 35 minutes and a throughput of 90 results per hour.
DiaSorin is a worldwide provider of specialty immunoassays in Infectious Disease testing with a history of expertise that spans over 25 years. The LIAISON® is the only fully automated chemiluminescence analyzer providing assays for the determination of IgG antibody response to measles, mumps, rubella and varicella zoster on a single platform.